Overview Dividends

(LLY) Eli Lilly - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5324571083

Insulin, Diabetes, Oncology, Immunology, Neuroscience

LLY EPS (Earnings per Share)

EPS Growth (3Y CAGR): 55.36%
EPS Trend (3Y Correlation): 52.7%

LLY Revenue

Revenue Growth (3Y CAGR): 37.70%
Revenue Trend (3Y Correlation): 96.8%

Description: LLY Eli Lilly September 24, 2025

Eli Lilly & Co. (NYSE: LLY) is a global pharmaceutical firm headquartered in Indianapolis, Indiana, that discovers, develops, and markets prescription medicines across the United States, Europe, China, Japan, and other international markets.

The company’s product slate is anchored by a broad diabetes franchise-including Basaglar, Humalog (U-100, U-200, Mix 75/25, Mix 50/50), Humulin (R, N, 70/30, U-500) and the newer agents Jardiance, Mounjaro, and Trulicity-as well as the obesity treatment Zepbound. In oncology, Lilly sells Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. Additional therapeutic areas cover inflammatory diseases (Olumiant, Taltz, Omvoh), central-nervous-system disorders (Cymbalta, Ebglyss), and migraine (Emgality).

Lilly maintains a robust collaboration network, partnering with Incyte, Boehringer Ingelheim, Roche/Genentech, AbCellera, Verge Genomics, AdvanCell, Chugai, and others to co-develop novel modalities such as targeted-alpha cancer therapies and myeloid-engager platforms for autoimmune disease.

Key financial and sector drivers (FY 2024): revenue of $28.5 bn (+12 % YoY), R&D spend of $6.2 bn (≈22 % of sales), and a 10-year average dividend yield of 2.1 %. The diabetes and obesity markets are expanding at 6-8 % CAGR globally, while oncology pipelines are seeing accelerated FDA approvals, both of which underpin Lilly’s growth outlook.

For a deeper quantitative view of LLY’s valuation dynamics, the ValueRay platform offers a granular, data-driven dashboard worth exploring.

LLY Stock Overview

Market Cap in USD	772,276m
Sub-Industry	Pharmaceuticals
IPO / Inception	1978-01-13

LLY Stock Ratings

Growth Rating	63.5%
Fundamental	84.1%
Dividend Rating	70.1%
Return 12m vs S&P 500	-5.49%
Analyst Rating	4.24 of 5

LLY Dividends

Dividend Yield 12m	0.65%
Yield on Cost 5y	4.21%
Annual Growth 5y	15.13%
Payout Consistency	99.5%
Payout Ratio	27.3%

LLY Growth Ratios

Growth Correlation 3m	89.4%
Growth Correlation 12m	-16.1%
Growth Correlation 5y	94.7%
CAGR 5y	36.76%
CAGR/Max DD 3y (Calmar Ratio)	1.07
CAGR/Mean DD 3y (Pain Ratio)	4.32
Sharpe Ratio 12m	1.51
Alpha	-1.44
Beta	0.461
Volatility	29.55%
Current Volume	5911.5k
Average Volume 20d	2610.8k
Stop Loss	879.6 (-3%)
Signal	2.05

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (18.41b TTM) > 0 and > 6% of Revenue (6% = 3.57b TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA 10.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 36.91% (prev 16.50%; Δ 20.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.14 (>3.0%) and CFO 16.06b <= Net Income 18.41b (YES >=105%, WARN >=100%)

Net Debt (32.71b) to EBITDA (25.12b) ratio: 1.30 <= 3.0 (WARN <= 3.5)

Current Ratio 1.55 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (898.8m) change vs 12m ago -0.69% (target <= -2.0% for YES)

Gross Margin 83.03% (prev 80.91%; Δ 2.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 62.37% (prev 54.05%; Δ 8.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 32.37 (EBITDA TTM 25.12b / Interest Expense TTM 717.4m) >= 6 (WARN >= 3)

Altman Z'' 3.75

(A) 0.19 = (Total Current Assets 62.07b - Total Current Liabilities 40.14b) / Total Assets 114.94b

(B) 0.19 = Retained Earnings (Balance) 22.25b / Total Assets 114.94b

(D) 0.22 = Book Value of Equity 19.64b / Total Liabilities 91.08b

Total Rating: 3.75 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 84.14

1. Piotroski 7.50pt = 2.50

2. FCF Yield 1.12% = 0.56

3. FCF Margin 15.18% = 3.80

4. Debt/Equity 1.79 = 1.08

5. Debt/Ebitda 1.30 = 1.30

6. ROIC - WACC (= 26.21)% = 12.50

7. RoE 102.3% = 2.50

8. Rev. Trend 96.84% = 7.26

9. EPS Trend 52.67% = 2.63

What is the price of LLY shares?

As of November 05, 2025, the stock is trading at USD 906.86 with a total of 5,911,474 shares traded.
Over the past week, the price has changed by +10.58%, over one month by +7.31%, over three months by +18.19% and over the past year by +13.35%.

Is Eli Lilly a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Eli Lilly (NYSE:LLY) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 84.14 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LLY is around 1038.32 USD . This means that LLY is currently undervalued and has a potential upside of +14.5% (Margin of Safety).

Is LLY a buy, sell or hold?

Eli Lilly has received a consensus analysts rating of 4.24. Therefore, it is recommended to buy LLY.

Strong Buy: 16
Buy: 7
Hold: 4
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the LLY price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	919.3	1.4%
Analysts Target Price	919.3	1.4%
ValueRay Target Price	1145.6	26.3%

LLY Fundamental Data Overview November 01, 2025

Market Cap USD = 772.28b (772.28b USD * 1.0 USD.USD)
P/E Trailing = 42.1936
P/E Forward = 27.1739
P/S = 12.9969
P/B = 40.2213
P/EG = 0.8974
Beta = 0.461
Revenue TTM = 59.42b USD
EBIT TTM = 23.22b USD
EBITDA TTM = 25.12b USD
Long Term Debt = 28.53b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.63b USD (from shortTermDebt, last quarter)
Debt = 42.51b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 32.71b USD (from netDebt column, last quarter)
Enterprise Value = 804.87b USD (772.28b + Debt 42.51b - CCE 9.91b)
Interest Coverage Ratio = 32.37 (Ebit TTM 23.22b / Interest Expense TTM 717.4m)
FCF Yield = 1.12% (FCF TTM 9.02b / Enterprise Value 804.87b)
FCF Margin = 15.18% (FCF TTM 9.02b / Revenue TTM 59.42b)
Net Margin = 30.99% (Net Income TTM 18.41b / Revenue TTM 59.42b)
Gross Margin = 83.03% ((Revenue TTM 59.42b - Cost of Revenue TTM 10.08b) / Revenue TTM)
Gross Margin QoQ = 82.91% (prev 84.27%)
Tobins Q-Ratio = 7.00 (Enterprise Value 804.87b / Total Assets 114.94b)
Interest Expense / Debt = 0.59% (Interest Expense 249.0m / Debt 42.51b)
Taxrate = 22.81% (1.65b / 7.23b)
NOPAT = 17.92b (EBIT 23.22b * (1 - 22.81%))
Current Ratio = 1.55 (Total Current Assets 62.07b / Total Current Liabilities 40.14b)
Debt / Equity = 1.79 (Debt 42.51b / totalStockholderEquity, last quarter 23.79b)
Debt / EBITDA = 1.30 (Net Debt 32.71b / EBITDA 25.12b)
Debt / FCF = 3.63 (Net Debt 32.71b / FCF TTM 9.02b)
Total Stockholder Equity = 18.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.02% (Net Income 18.41b / Total Assets 114.94b)
RoE = 102.3% (Net Income TTM 18.41b / Total Stockholder Equity 18.01b)
RoCE = 49.90% (EBIT 23.22b / Capital Employed (Equity 18.01b + L.T.Debt 28.53b))
RoIC = 33.55% (NOPAT 17.92b / Invested Capital 53.43b)
WACC = 7.33% (E(772.28b)/V(814.78b) * Re(7.71%) + D(42.51b)/V(814.78b) * Rd(0.59%) * (1-Tc(0.23)))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.29%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈9.02b ; Y1≈5.92b ; Y5≈2.71b
Fair Price DCF = 59.48 (DCF Value 53.24b / Shares Outstanding 895.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 52.67 | EPS CAGR: 55.36% | SUE: 1.26 | # QB: 2
Revenue Correlation: 96.84 | Revenue CAGR: 37.70% | SUE: 2.36 | # QB: 2

Additional Sources for LLY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle